These studies indicate that administration of low-dose cisplatin and gemcitabine is safe and feasible in bladder cancer patients with impaired renal function and shows adequate levels of efficacy.
Recent advances in immunotherapy and combination therapies are revolutionizing the treatment landscape for both metastatic ...
The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...
Source: Getty Images Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder cancer, according to ... durvalumab (1500 mg every 3 weeks ...
Hosted on MSN9mon
Intravesical gemcitabine/docetaxel as an alternative therapy for patients with non-muscle-invasive bladder cancerBladder cancer is one of the more common cancers ... Initial results with gemcitabine (Gem) and mitomycin C (MMC) appeared promising but shortages in MMC led to the need to substitute docetaxel ...
For patients with advanced or metastatic pancreatic cancer, gemcitabine is the standard therapy; however, although gemcitabine therapy increases overall survival, response rates are low.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback